Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia: Initial results from the BFORE trial Meeting Abstract
| Authors: | Brümmendorf, T. H.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; Cortes, J. E.; on behalf of the BFORE Study Investigators |
| Abstract Title: | Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia: Initial results from the BFORE trial |
| Meeting Title: | 22nd Congress of the European Hematology Association (EHA) |
| Journal Title: | Haematologica |
| Volume: | 102 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 22-25 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2017-06-26 |
| Start Page: | 152 |
| Language: | English |
| ACCESSION: | WOS:000404127001319 |
| PROVIDER: | wos |
| PMCID: | PMC5492673 |
| Notes: | Meeting Abstract: S425 -- Source: Wos |
MSK Authors
-
267Mauro